TY - JOUR T1 - Oral and inhalation usage of acetylcysteine in patients with COPD JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.congress-2019.PA2043 VL - 54 IS - suppl 63 SP - PA2043 AU - Galyna Gumeniuk AU - Nina Kuzmenko AU - Oleh Iaremenko AU - Dmytro Dobrianskiy AU - Roman Ilnytskyi Y1 - 2019/09/28 UR - http://erj.ersjournals.com/content/54/suppl_63/PA2043.abstract N2 - Background: Some patients with COPD in a stable phase and with a baseline therapy continue to complain of shortness of breath and cough with sputum production difficulty. These patients additionally take mucolytics such as acetylcysteine.Aims and Objectives: To determine the efficacy and safety of the nebulized therapy of acetylcysteine compared to its oral administration in patients with COPD.Methods: The study included 31 patients with COPD without exacerbation. They were divided into 2 groups. The first group (n=13) took 600 mg/day acetylcysteine orally, and the second one (n=18) inhaled 600 mg/day acetylcysteine from a nebulizer for 10 days receiving the unchanged baseline therapy. Data from questionnaires (CAT, mMRC, CCQ) were evaluated, day and night cough symptoms were assessed on a scale, as well as spirometry and sputum analysis were done.Results: The first group showed an improvement in their condition based on CCQ score (decrease by 15.1%, p<0.04). In other investigations significant dynamics was not registered. There were significant positive changes in CAT results (decrease by 16.8% compared to initial data), reduction in the night cough symptoms (by 36.4%) in the group of patients inhaling acetylcysteine. CCQ, mMRC and daytime cough symptoms values did not change significantly. The increase in FEV1 at 10% (p=0.01) and the decrease in the number of leukocytes in sputum were also registered in second group. Side effects developed infrequently.Conclusions: In patients with COPD who have symptoms in a stable phase, the inhalation of acetylcysteine has a greater effect on the disease manifestation comparing with the oral administration in the same daily dose; the tolerability of treatment is satisfactory.FootnotesCite this article as: European Respiratory Journal 2019; 54: Suppl. 63, PA2043.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only). ER -